Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023PRNewsWire • 09/22/23
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023PRNewsWire • 09/14/23
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023PRNewsWire • 09/11/23
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023GlobeNewsWire • 08/30/23
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid TumorsGlobeNewsWire • 08/24/23
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business CombinationGlobeNewsWire • 08/15/23
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public CompanyGlobeNewsWire • 08/09/23
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve ExtensionBusiness Wire • 05/17/23
NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IVGlobeNewsWire • 04/15/23
Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021Business Wire • 07/09/21
Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public OfferingBusiness Wire • 06/02/21
Graf Acquisition Corp. IV Announces Closing of $150 Million Initial Public OfferingBusiness Wire • 05/25/21